{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:11:45Z","timestamp":1781151105687,"version":"3.54.1"},"reference-count":19,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Ibrutinib is a tyrosine kinase inhibitor that is increasingly prescribed in chronic lymphocytic leukemia (CLL). Invasive fungal infections (IFIs) have been reported early after ibrutinib initiation. Timing of IFIs is within 6 months and commonly reported fungal infections include Cryptococcus, Aspergillus, and Pneumocystis. Currently, there are no recommendations for routine prophylaxis against IFIs in patients receiving ibrutinib for CLL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate the incidence of IFIs in patients receiving ibrutinib for CLL in first-line and relapsed\/refractory (R\/R) settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, cohort study of patients diagnosed with CLL and initiated on ibrutinib in the Veterans Health Administration (VHA) from October 1, 2013 to March 31, 2018. Patients were included if diagnosed with a proven or probable IFI from the start date of ibrutinib to 30 days after the last dose of ibrutinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen out of 1069 patients met inclusion criteria for IFI while on ibrutinib for CLL. All patients included were male with a median age of 78 years. Fifty percent of patients were initiated on ibrutinib within 3 months of last chemotherapy. IFIs occurred within 3 months (50%) and 6 months (71%) of ibrutinib initiation. Seventy-one percent of patients were continued on ibrutinib with concurrent IFI diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The reported IFI incidence of 1.3% is comparable to current estimates of 1.2%. Future studies should examine the relationship of ibrutinib and incidence of IFIs in first-line and R\/R settings in addition to identifying clinical risk factors predisposing patients to IFIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231181113","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T01:54:20Z","timestamp":1686621260000},"page":"673-677","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran\u2019s healthcare administration"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9958-2618","authenticated-orcid":false,"given":"Cassandra","family":"Walker","sequence":"first","affiliation":[{"name":"Pharmacy Department, South Texas Veterans Health Care System, San Antonio, TX, USA"},{"name":"Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, TX, USA"},{"name":"Pharmacotherapy Education and Research Center, School of Medicine, University of Texas Health, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0261-2863","authenticated-orcid":false,"given":"Amy","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Pharmacy Department, South Texas Veterans Health Care System, San Antonio, TX, USA"},{"name":"Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, TX, USA"},{"name":"Pharmacotherapy Education and Research Center, School of Medicine, University of Texas Health, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra","family":"Nooruddin","sequence":"additional","affiliation":[{"name":"Pharmacy Department, South Texas Veterans Health Care System, San Antonio, TX, USA"},{"name":"Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, TX, USA"},{"name":"Pharmacotherapy Education and Research Center, School of Medicine, University of Texas Health, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R","family":"Frei","sequence":"additional","affiliation":[{"name":"Pharmacy Department, South Texas Veterans Health Care System, San Antonio, TX, USA"},{"name":"Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, TX, USA"},{"name":"Pharmacotherapy Education and Research Center, School of Medicine, University of Texas Health, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"bibr1-10781552231181113","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409056283"},{"key":"bibr2-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131646"},{"key":"bibr3-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"bibr4-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"bibr5-10781552231181113","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Chronic lymphocytic leukemia\/small lymphocytic lymphoma. Version 2.2023, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf (accessed 18 March 2023)."},{"key":"bibr6-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"bibr7-10781552231181113","author":"Michael F","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"bibr8-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-722991"},{"key":"bibr9-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix687"},{"key":"bibr10-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy175"},{"key":"bibr11-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947"},{"key":"bibr12-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2009.08.006"},{"key":"bibr13-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1008"},{"key":"bibr14-10781552231181113","author":"Lui Y","journal-title":"Prev Chronic Dis"},{"key":"bibr15-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.21.3252"},{"key":"bibr16-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13001"},{"key":"bibr17-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1876863"},{"key":"bibr18-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-818286"},{"key":"bibr19-10781552231181113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148716"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231181113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231181113","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231181113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:38Z","timestamp":1777688918000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231181113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1177\/10781552231181113"],"URL":"https:\/\/doi.org\/10.1177\/10781552231181113","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}